- Have a BRCA1 or BRCA2 mutation
- Have confirmed metastatic breast cancer
- Her2neu negative (or Her2neu positive and have received previous anti-Her2neu therapy or are ineligible for anti-Her2neu therapy)
- Have measurable disease
Learn more about the study, on the FORCE website.
FORCE will also host a free webinar: Updates on PARP Inhibitor Research.
Date: Thursday, February 28, 2013
Time: 12pm -1pm ET
Speaker: Susan Domchek, MD, Executive Director of the Basser Research Center for BRCA
More info: http://www.facingourrisk.org/events/webinars/index.php#upcoming
While you’re at it
Help FORCE and Celebration Health by participating in a survey about long-term follow-up healthcare for preivors and survivors. This will provide important info about long-term health concerns for women with BRCA and other hereditary cancer syndromes.